Literature DB >> 8480421

Temperature-sensitive mutants in the vaccinia virus A18R gene increase double-stranded RNA synthesis as a result of aberrant viral transcription.

C D Bayliss1, R C Condit.   

Abstract

Mutations in the vaccinia gene A18R cause activation of the cellular ribonucleolytic 2-5A pathway. To determine the mechanism of 2-5A pathway activation, mutant infections were analyzed for synthesis of double-stranded RNA and for transcription of individual virus genes. At late times postinfection, A18R mutant-infected cells contained an increased amount of complementary RNA and a higher steady state level of RNA from regions of the genome transcribed normally only early in the infection. The phenotype of A18R ts mutants is indistinguishable from that of wild-type infections done in the presence of isatin-beta-thiosemicarbazone (IBT). Actinomycin D is a potent inhibitor of activation of the 2-5A pathway in IBT-treated wt infections. Based on these observations, we conclude that the phenotype induced by A18R mutants or by IBT treatment of wt infections is caused by a loss of control of late viral transcription.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480421     DOI: 10.1006/viro.1993.1256

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  Viral double-stranded RNAs from vaccinia virus early or intermediate gene transcripts possess PKR activating function, resulting in NF-kappaB activation, when the K1 protein is absent or mutated.

Authors:  Kristen L Willis; Jeffrey O Langland; Joanna L Shisler
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

2.  Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression.

Authors:  Susan Parrish; Bernard Moss
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins.

Authors:  Jeffrey O Langland; John C Kash; Victoria Carter; Matthew J Thomas; Michael G Katze; Bertram L Jacobs
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis.

Authors:  Ping Zhang; Bertram L Jacobs; Charles E Samuel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

5.  The vaccinia virus A18R DNA helicase is a postreplicative negative transcription elongation factor.

Authors:  Y Xiang; D A Simpson; J Spiegel; A Zhou; R H Silverman; R C Condit
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Transcription of a vaccinia virus late promoter template: requirement for the product of the A2L intermediate-stage gene.

Authors:  A L Passarelli; G R Kovacs; B Moss
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells.

Authors:  K V Kibler; T Shors; K B Perkins; C C Zeman; M P Banaszak; J Biesterfeldt; J O Langland; B L Jacobs
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses.

Authors:  Shin-Wu Liu; George C Katsafanas; Ruikang Liu; Linda S Wyatt; Bernard Moss
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

9.  Vaccinia virus gene A18R encodes an essential DNA helicase.

Authors:  D A Simpson; R C Condit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Genetic screen of a mutant poxvirus library identifies an ankyrin repeat protein involved in blocking induction of avian type I interferon.

Authors:  Stephen M Laidlaw; Rebecca Robey; Marc Davies; Efstathios S Giotis; Craig Ross; Karen Buttigieg; Stephen Goodbourn; Michael A Skinner
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.